TX-MYTHICAL-GAMES
30.5.2024 19:30:28 CEST | Business Wire | Press release
Pudgy Penguins, the brand development company behind the series of globally recognized Pudgy Penguins characters, and next-generation gaming technology studio Mythical Games today announced a partnership to create a unique web3-enabled mobile video game. The partnership unites the creators of the globally recognized Pudgy Penguins characters and the gaming studio behind two of the most successful blockchain games ever, NFL Rivals and Blankos Block Party.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530595937/en/
Details of the forthcoming game developed in conjunction with Mythical Games were announced at Consensus 2024. The upcoming mobile game will be an immersive video game drawing upon the lore and humor that have made Pudgy Penguins so beloved, coupled with AAA quality, playability, and accessibility synonymous with Mythical Games' title NFL Rivals. The new game is scheduled to launch on the Mythical platform in 2025, home to NFL Rivals, with over 5 million players, and the Mythos Chain (MYTH), with over one million active wallets.
“Web3 in gaming is evolving quickly, but one thing that hasn’t changed is the need for games to be powered by strong communities and great gameplay,” said John Linden, Mythical Games CEO. “Pudgy Penguins is the only web3 project to truly go mainstream through their incredible retail partnerships with Walmart and Target and their rapidly growing social media following. We are excited to combine their efforts with a game that will be played by millions. Building this with Mythical Games on the Mythical Platform and Mythos Chain, already used by millions of consumers, is going to be a major driver to further push web3 with mainstream consumers.”
Luca Netz, CEO of Pudgy Penguins said: “When we decided to create a mobile-first AAA blockchain-based Pudgy Penguins game, working with Mythical Games is something that excited me. Our growth strategy that has reached millions, combined with Mythical Games’ experience and success with gaming, sets up this endeavor for success. We can’t wait to show the Pudgy Penguins community what’s in store and solicit their feedback as development ramps up.”
In the build-up to its release, Pudgy Penguins holders will be treated to exclusive content, sneak peeks of in-game footage and given the opportunity to help shape key aspects of the game’s development. The game is designed to appeal to the Pudgy Penguins community as well as the broader gaming market to further grow the Pudgy Penguins’ brand and ethos.
Ahead of the game's launch in 2025, interested players can join Pudgy Penguins Discord, and follow Pudgy Penguins (@pudgypenguins) and Mythical Games (@playmythical) Twitter/X accounts to stay updated on the upcoming game.
About Pudgy Penguins
Pudgy Penguins is dedicated to making Web3 accessible to everyone by creating innovative products that enable seamless onboarding. Their focus on community empowerment and building brand awareness has made them a leader in the Web3 space while also disrupting the traditional web2, retail sphere. They're committed to impacting the everyday consumer and shaping the future of Web3.
Learn more: https://www.pudgypenguins.com/
About Mythical Games
Acknowledged by Fast Company’s World Changing Ideas 2021 and recently Forbes’ Best Startup Employers (2024), Mythical Games is a next-generation game company creating world-class games and empowering players to take ownership of their in-game assets through the use of blockchain technology. The team has helped develop major franchises, including Call of Duty, Call of Duty Mobile, World of Warcraft, Diablo, Overwatch, Magic: The Gathering, EA Madden, Harry Potter Hogwarts Mystery, Marvel Strike Force, Modern Warfare 3, and Skylanders.
The Mythical Marketplace, the first in-game blockchain Marketplace on iOS and Android, provides gamers with ownership and control over the purchase and sale of digital assets, while the Mythical Platform protects gamers that may be new to blockchain through a custodial wallet for their digital items.
Mythical Games is one of the 22 founding member companies of the Mythos Foundation (http://mythos.foundation) utilizing the Mythos Chain as its blockchain and Mythos’ MYTH token as the utility token for the Mythical Marketplace.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530595937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom